The GLP-1 conversation keeps expanding. We’ve covered Ozempic face, hair loss, muscle loss and what happens after you stop the medication. Now, a new NBER working paper by economist Rebecca Diamond, titled “GLP-1-Induced Weight Loss and the Female Obesity Penalty,” adds an uncomfortable new layer: GLP-1–related weight loss may also be linked to who lands a job and who finds a partner.
According to the paper, among women who were not employed before starting a GLP-1, the share who had a job after at least 18 months was nearly 27 percentage points higher than among comparable women who wanted to start treatment but had not yet done so. Among women who were single at the outset, the share who were married or living with a partner was nearly 29 percentage points higher. Women who were already employed or partnered saw little measurable change, suggesting the biggest differences emerged when new jobs or relationships were being formed.
Researchers say the findings are consistent with what’s known as the “female obesity penalty,” the long-documented pattern of women with obesity facing greater barriers in hiring, pay and dating. The paper doesn’t suggest GLP-1s improve careers or relationships once they’re already established. Instead, the biggest differences appeared when new jobs or romantic partnerships were being formed, suggesting weight may play a larger role in those early decisions. Still, this is a working paper that has not yet been peer reviewed, and the researchers can’t say whether the shifts were driven by weight loss itself or by related factors such as improved health or greater confidence.
One detail is hard to ignore: About 40 percent of the GLP-1 users in the study paid roughly $299 a month out of pocket. If future research confirms that these medications can help reduce some of the bias women face at work and in dating, access becomes about more than health. It raises a more uncomfortable question: Who can afford that advantage?
